Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 4;104(4):827–834. doi: 10.3324/haematol.2018.202267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 2. — Outcome of patients in the first year after allogeneic stem cell transplantation and after onset of acute graft-versus-host disease when stratified according to pre-transplant asymmetric dimethylarginine quartiles. (A, B) Higher pre-transplant asymmetric dimethylarginine (ADMA) serum levels were associated with lower probabilities of overall survival (OS) in (A) the first year after allogeneic stem cell transplantation and (B) after the onset of acute graft-versus-host disease (GvHD). (C, D) The probabilities of progression-free survival (PFS) in (C) the first year after transplantation and (D) after the onset of acute GvHD were substantially lower in patients with higher pre-transplant ADMA levels. (E, F) Higher pre-transplant ADMA serum levels were associated with higher incidences of non-relapse mortality (NRM) in (E) the first year after allografting and (F) after the onset of acute GvHD. (G) In contrast, the ncidence of relapse during the first post-transplant year was not affected by pre-transplant ADMA levels. Note: Quartiles were chosen for reasons of visualization of the continuous ADMA effect which was observed for every 2-fold change in multivariable analyses (Tables 2 and 3). For this reason, and since pre-transplant ADMA values were not normally distributed, there is an overlap of the second and third quartile. Q1-4, quartiles of the ADMA distribution.